Overview

PRI-VENT FSGS: Preemptive Rituximab to Prevent Recurrent Focal Segmental Glomerulosclerosis Post-Transplant

Status:
Recruiting

Trial end date:
2023-12-31

Target enrollment:

Participant gender:

Summary

This is a phase III, multicenter, randomized, open label, clinical trial to test that hypothesis that plasmapheresis plus rituximab prior to kidney transplantation can prevent recurrent FSGS in children and adults.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

University of Minnesota
University of Minnesota - Clinical and Translational Science Institute

Collaborator:

United States Department of Defense

Treatments:

Rituximab